These findings support Ropeg-IFNa use across MPN subtypes in practice and highlight the value of tracking JAK2 V617F burden alongside proactive tolerability monitoring to optimize outcomes in real-world MPN patients. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.